Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-3000 PK and Safety Study with Paroxetine
NCT04650542Phase 1Completed
- Sponsor
- HUYABIO International, LLC
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sulcardine in Atrial fibrillation (AFib), sponsored by HUYABIO International, LLC. Primary endpoints: Maximum observed plasma concentration at 72 hours, Area Under the Curve from time 0 to last measurable concentration at 72 hours and 1 more. Started Feb 2021; status: completed.
02
Drugs
sulcardine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04650542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650542.